Morgan Stanley expects five of its top Asia stock picks to rise by more than 50% over the next 12 months. The Wall Street bank is bullish on a set of Asian stocks as the broad MSCI Asia Pacific equities index has entered a new bull market, rising 25% from last October's low. The investment bank said the makeup of pan-Asian stocks is changing rapidly.
The decision declared invalid a patent related to a drug formulation of mirabegron, a medication used to treat overactive bladder. The decision will allow other pharma companies to manufacture generic versions of the drug. The patent was a key part of Astellas' medium-term business plan. "The likelihood of generics being immediately released in May 2024 is low," Morgan Stanley analysts Shinichiro Muraoka and Jaeheon Lee said in a note to clients on June 12.